Health  Vol.5 No.7 B , July 2013
A candidate identification questionnaire for postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study—BONCURE study
Show more

A candidate identification questionnaire (CIQ) was tested to determine its predictive value for patient-reported satisfaction in patients switched from once-weekly or once-daily treatment with a bisphosphonate to once-monthly dosing. This was a prospective, open-label, multicenter international study in patients with postmenopausal osteoporosis who had been receiving once-daily or once-weekly alendronate or risendronate for at least 3 months. Patients completed a CIQ, then commenced 150 mg monthly ibandronate for 6 months. Patients completed the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-QTM) at baseline for 6 months. Scores were converted to composite satisfaction scores (CSS, scale 0-100). Totally 677 patients completed a CIQ, 645 were enrolled in the treatment phase and comprised the intent-to-treat (ITT) population, and 630 completed the study. In the ITT population, 68.1% patients answered “yes” to one or more CIQ questions. OPSAT-Q scores increased for the convenience, quality of life and overall satisfaction domains (p < 0.001). Decreases in scores for the side effects domains were significant (p < 0.001) in the CIQ “yes” group, but not for the degree of bother (decrease in mean of 0.1 points, p = 0.50) or duration (no change, p = 0.84) of non-gastrointestinal side effects. Of 638 patients who completed the preference questionnaire, 93.0% of patients preferred the once-monthly dosing schedule and 563 patients (90.7%) found it more convenient. The most common adverse events were dyspepsia (1.9%), nausea (1.1%), and upper abdominal pain (0.9%). Patients are likely to prefer treatment with monthly ibandronate to a weekly or monthly bisphosphonate irrespective of their stated preference before switching treatment.

Cite this paper: Kutsal, Y. , Eskiyurt, N. , Irdesel, J. , Sepici, V. , Ugurlu, H. , Kirazli, Y. , Ardic, F. , Korsic, M. , Vlak, T. , Grlickov, M. , Temelkova, S. , Lazarov, M. , Pilipovic, N. , Popovic, V. , Dimic, A. , Kovacev, B. , Ruci, D. , Tafaj, A. , Kucukalic-Selimovic, E. , Avdic, D. , Seleskovic, H. , Pejicic, S. , Butun, B. , Akyuz, G. , Cerrahoglu, L. , Sendur, O. , Yalcin, P. , Oncel, S. , Saridogan, M. , Sarpel, T. , Tosun, M. , Senel, K. , Gursoy, S. , Canturk, F. , Demir, H. , Miskic, B. , Krpan, D. , Skreb, F. , Grazio, S. , Crncevic-Orlic, Z. , Ozdener, F. and Oncel, H. (2013) A candidate identification questionnaire for postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study—BONCURE study. Health, 5, 30-40. doi: 10.4236/health.2013.57A2004.

[1]   Papapoulos, S.E. (2001) Bisphosphonates in the management of postmenopausal osteoporosis. In: Marcus, R., Feldman, D. and Kelsey, J., Eds., Osteoporosis, 2nd Edition, Academic Press, New York, 631-650. doi:10.1016/B978-012470862-4/50073-8

[2]   Schnitzer, T., Bone, H.G., Crepaldi, G., Adami, S., McClung, M., et al. (2002) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group, Aging, Milano, 12, 1-12.

[3]   Lombas, C., Hakim, C. and Zanchetta, J.R. (2000) Compliance with alendronate treatment in an osteoporosis clinic. Journal of Bone and Mineral Research, 15, M406.

[4]   Finigan, J., Bainbridge, P.R. and Eastell, R. (2001) Adherence to osteoporosis therapies. Osteoporosis International, 12, 110.

[5]   Hamilton, B., McCoy, H. and Taggart, H. (2001) Tolerability and compliance with risendronate in clinical practice. Osteoporosis International, 12, 111.

[6]   Reginster, J.Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J.J., Silverman, S.L., Christiansen, C., Rowell, L., Mairon, N., Bonvoisin, B., Drezner, M.K., Emkey, R., Felsenberg, D., Cooper, C., Delmas, P.D. and Miller, P.D. (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Annals of the Rheumatic Diseases, 65, 654-661. doi:10.1136/ard.2005.044958

[7]   Stakkestad, J.A., Lakatos, P., Lorenc, R., Sedarati, F., Neate, C. and Reginster, J.Y. (2008) Monthly oral ibandronate is effective and well tolerated after 3 years: The MOBILE long-term extension. Clinical Rheumatology, 27, 955-960. doi:10.1007/s10067-007-0824-6

[8]   Binkley, N., Martens, M.G., Silverman, S.L., Derman, R.J., Greenwald, M., Kohles, J.D. and Bachmann, G.A. (2009) Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates. Southern Medical Journal, 102, 486-492. doi:10.1097/SMJ.0b013e31819ed0dd

[9]   Bonnick, S.L., Silverman, S., Tanner, S.B., Martens, M., Bachmann, G., Kohles, J.D. and Civitelli R. (2009) Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. Journal of Womens Health, 18, 935-943. doi:10.1089/jwh.2008.1064

[10]   Flood, E.M., Beusterien, K.M., Green, H., Shikiar, R., Baran, R.W., Amonkar, MM. and Cella, D. (2006) Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health and Quality of Life Outcomes, 4, 42. doi:10.1186/1477-7525-4-42

[11]   Simon, J.A., Lewiecki, E.M., Smith, M.E., Petruschke, R.A., Wang, L. and Palmisano, J.J. (2002) Patient preference for once-weekly alendronate 70 mg versus oncedaily alendronate 10 mg: A multicenter, randomized, openlabel, crossover study. Clinical Therapeutics, 24, 1871-1886. doi:10.1016/S0149-2918(02)80085-6

[12]   Cotte, F.E., Fardelione, P., Mercier, F., Gaudin, A.F. and Roux C. (2009) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporosis International, 29, 125-139.

[13]   Gold, D.T., Safi, W. and Trish, H. (2006) Patient preference and adherence: Comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Current Medical Research and Opinion, 22, 2382-2391. doi:10.1185/030079906X154042

[14]   Silverman, S.L., Schousboe, J.T. and Gold, D.T. (2011) Oral bisphosphonate compliance and persistence: A matter of choice? Osteoporosis International, 22, 21-26. doi:10.1007/s00198-010-1274-6

[15]   Vlak, T., Kastelan, D., Lozo, P., Aljinovic, J., Gradiser, M., et al. (2011) Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia. Clinical Rheumatology, 30, 1549-1554. doi:10.1007/s10067-011-1858-3

[16]   Cramer, J.A., Gold, D.T., Silverman, S.L. and Leviecki, E.M. (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis International, 18, 1023-1031. doi:10.1007/s00198-006-0322-8

[17]   Vrijens, B., Vincze, G., Krisanto, P., Urquhart, J. and Burnier, M. (2008) Adherence to prescribed antihypertensive drug treatments: Longitudinal study of electronically compiled dosing histories. British Medical Journal, 336, 1114-1117. doi:10.1136/bmj.39553.670231.25

[18]   Claxton, A.J., Cramer, J. and Pierce, C. (2001) A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics, 23, 1296-1310. doi:10.1016/S0149-2918(01)80109-0

[19]   Sclar, D.A. (1991) Improving medication compliance: A review of selected issues. Clinical Therapeutics, 13, 436-440.

[20]   Emkey, R., Koltun, W., Beusterien, K., Seidman, L., Kivitz, A., Devas, V. and Masanauskaite, D. (2005) Patient preference for once-monthly ibandronate versus onceweekly alendronate in a randomized, open-label, crossover trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Current Medical Research and Opinion, 21, 1895-1903. doi:10.1185/030079905X74862

[21]   Cloves, J.A., Peel, N.F. and Estell, R. (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism, 89, 1117-1123. doi:10.1210/jc.2003-030501

[22]   Delmas, P.D., Vrijens, B., Estell, R., Roux, C., Pois, H.A., Ringe, J.D., Grauser, A., Cahall, D. and Watts, N.B. (Improvement Measurement of Persistence on Actonell Treatment Investigators) (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 92, 1296-1305. doi:10.1210/jc.2006-1526